Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.
Amedeo Ferdinando CapettiMaria Vittoria CossuGaetana SterrantinoGiorgio BarbariniSimona Di GiambenedettoGiuseppe Vittorio De SocioGianCarlo OrofinoAntonio Di BiagioBenedetto M CelesiaStefano RusconiBarbara ArgenteriGiuliano RizzardiniPublished in: The Annals of pharmacotherapy (2018)
Switching to DTG plus RPV improved viral suppression and LDL-C/HDL-C ratio.